Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models
Drug Resistance Updates · 2024-05 · 74 · 101078
DOI: 10.1016/j.drup.2024.101078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-05. Verfasst von Lu Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
AIMS: Human epidermal growth factor receptor 2 (HER2) is an oncogenic receptor tyrosine kinase amplified in approximately 20% of breast cancer (BC). HER2-targeted therapies are the linchpin of treating HER2-positive BC. However, drug resistance is common, and the main resistance mechanism is unknown. We tested the hypothesis that drug resistance results mainly from inadequate or lack of inhibition of HER2 and its family member epidermal growth factor receptor (EGFR). METHODS: We used clinically relevant cell and tumor models to assess the impact of targeted degradation of HER2 and EGFR on trastuzumab resistance. Trastuzumab is the most common clinically used HER2 inhibitor. Targeted degradation of HER2 and EGFR was achieved using recombinant human protein PEPDG278D, which binds to the extracellular domains of the receptors. siRNA knockdown was used to assess the relative importance of EGFR and HER2 in trastuzumab resistance. RESULTS: Both HER2 and EGFR are overexpressed in all trastuzumab-resistant HER2-positive BC cell and tumor models and that all trastuzumab-resistant models are highly vulnerable to targeted degradation of HER2 and EGFR. Degradation of HER2 and EGFR induced by PEPDG278D causes extensive inhibition of oncogenic signaling in trastuzumab-resistant HER2-positive BC cells. This is accompanied by strong growth inhibition of cultured cells, orthotopic patient-derived xenografts, and metastatic lesions in the brain and lung of trastuzumab-resistant HER2-positive BC. siRNA knockdown indicates that eliminating both HER2 and EGFR is necessary to maximize therapeutic outcome. CONCLUSIONS: This study unravels the therapeutic vulnerability of trastuzumab-resistant HER2-positive BC and shows that an agent that targets the degradation of both HER2 and EGFR is highly effective in overcoming drug resistance in this disease. The findings provide new insights and innovations for advancing treatment of drug-resistant HER2-positive breast cancer that remains an unmet problem.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA.
- Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, School of Pharmacy, Richmond, VA, USA.
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
- Translational Research Department, Institute of Curie, Paris, France.
- Department of Pathology, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA.
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA; Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. Electronic add…
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- VCU Massey Cancer Center
Zitieren
APA
Yang, L., Bhattacharya, A., Peterson, D., Li, Y., Liu, X., Marangoni, E., Robila, V., & Zhang, Y. (2024). Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models. Drug Resistance Updates, 74, 101078. https://doi.org/10.1016/j.drup.2024.101078
Vancouver
Yang L, Bhattacharya A, Peterson D, Li Y, Liu X, Marangoni E, et al. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models. Drug Resistance Updates. 2024;74:101078. doi:10.1016/j.drup.2024.101078
BibTeX
@article{Yang2024,
author = {Yang, Lu and Bhattacharya, Arup and Peterson, Darrell and Li, Yun and Liu, Xiaozhuo and Marangoni, Elisabetta and Robila, Valentina and Zhang, Yuesheng},
title = {Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models},
journal = {Drug Resistance Updates},
year = {2024},
volume = {74},
pages = {101078},
doi = {10.1016/j.drup.2024.101078}
}
EUVIMED